Abstract
Purpose:
To model juvenile-onset myopia progression as a function of race/ethnicity, age, sex, parental history of myopia, and time spent reading or in outdoor/sports activity.
Methods:
Subjects were 594 children in the Collaborative Longitudinal Evaluation of Ethnicity and Refractive Error (CLEERE) Study with at least three study visits: one visit with a spherical equivalent (SPHEQ) less myopic/more hyperopic than −0.75 diopter (D), the first visit with a SPHEQ of −0.75 D or more myopia (onset visit), and another after myopia onset. Myopia progression from the time of onset was modeled using cubic models as a function of age, race/ethnicity, and other covariates.
Results:
Younger children had faster progression of myopia; for example, the model-estimated 3-year progression in an Asian American child was −1.93 D when onset was at age 7 years compared with −1.43 D when onset was at age 10 years. Annual progression for girls was 0.093 D faster than for boys. Asian American children experienced statistically significantly faster myopia progression compared with Hispanic (estimated 3-year difference of −0.46 D), Black children (−0.88 D), and Native American children (−0.48 D), but with similar progression compared with White children (−0.19 D). Parental history of myopia, time spent reading, and time spent in outdoor/sports activity were not statistically significant factors in multivariate models.
Conclusions:
Younger age, female sex, and racial/ethnic group were the factors associated with faster myopic progression. This multivariate model can facilitate the planning of clinical trials for myopia control interventions by informing the prediction of myopia progression rates.
The prevalence of myopia varies around the world. A report from the United States indicated that roughly one-third of those 20 years and older were myopic.
1 Studies from Asia report a higher prevalence of myopia compared with the United States. For example, in Korea, 96.5% of male military enlistees were reported to be myopic.
2 He et al.
3 found that 78% of Chinese 15-year-olds were myopic, whereas 62.5% of 12-year-old children in Hong Kong were myopic.
4 Given that there is no accepted method to prevent the onset of myopia, identifying those children at greatest risk of myopia progression is a logical goal for clinicians and researchers.
Many studies have reported rates of myopia progression, most frequently based on data for the single-vision spectacle or placebo group in clinical trials evaluating interventions for myopia control. Reports of myopia progression from Singapore and Hong Kong found similar rates of progression, roughly −0.60 diopter (D)/yr.
5–8 Several other studies found greater average yearly progression rates, between −0.80 D and −1.20 D/yr,
9–11 although Hasebe et al.
9 found that older children's myopia progressed more slowly than younger children (−1.03 D/yr vs. −1.36 D/yr). A cohort from Singapore further illustrates the declining rate of myopic progression with increasing age. During the first year, there was a progression of −0.88 D in a group of 7- to 9-year-old children, with the change slowing to −0.67 D during the second year. By the third year, the change was only −0.48 D.
12 A study in China found that both age and sex differentially affected progression, that is, younger children progressed faster, as did females.
13
In comparison to children in Asian countries, myopia progression rates reported for children in the United States tend to be slightly slower. In the placebo group in a US-based study of pirenzepine in a predominantly White sample,
14 the average myopia progression was −0.53 D per year. Gwiazda et al.
15 had a slightly more racially mixed sample aged 6 to 11 years and reported a 3-year myopia progression of −1.48 D in the single-vision lens group, with progression of −0.60 D in the first year. Age, sex, and race/ethnicity all played roles in the amount of myopic progression.
16
A greater number of myopic parents has also been associated with a faster rate of progression. Kurtz et al.
17 reported that progression over 5 years was −1.81 D among children in the single-vision lens group with no myopic parents compared with −2.59 D in children with two myopic parents. Saw et al.
7 reported that having two myopic parents added −0.43 D every 6 months to the rate of myopia progression. In general, the annual myopia progression rates published to date range from −0.50 D to −0.90 D per year.
The data investigating patterns for progression in subgroups beyond sex and age are limited. Specifically, there are limited data on a variety of racial/ethnic groups in conjunction with age of myopia onset and other potential predictors of progression rate. With the exception of a subset of children from the Singapore study,
18 the children typically presented in the literature are prevalent myopes, having been diagnosed some time prior to study entry. Known age of onset, as opposed to depending on parental recall or clinic records, allows for analysis of the effect of the age of onset on the rate of progression, for example, does the rate of myopia progression of an 11-year-old child differ depending on whether the myopia onset was at age 7, 9, or 10 years? Identifying the factors associated with myopia progression could also help target those groups that might benefit the most from early treatment to prevent or slow myopia progression. Detailed quantitative models relating risk factors to rates of progression are necessary for such identification. The success of several therapies to slow myopia progression, such as low-dose atropine and soft multifocal contact lenses, makes randomization of children to placebo or standard groups in future clinical trials less likely due to ethical concerns.
19–22 Judging efficacy against an untreated control group may depend on comparison to historical, untreated control groups. Using data from the Collaborative Longitudinal Evaluation of Ethnicity and Refractive Error (CLEERE) Study, myopia progression models by race/ethnicity, age at first myopic visit, sex, parental myopia, and environmental exposures are presented to address these questions.
All analyses were done using SAS version 9.4 (SAS Institute, Cary, NC, USA) for Windows. The MIXED procedure was used for modeling. Fitting SPHEQ as a cubic in time provided enough flexibility to adequately fit myopia progression after onset. The base model had the following form:
\begin{equation*}\begin{array}{@{}l@{}} SPHE{Q_{Ti}} = \left( {{\gamma _0} + {u_{0i}}} \right) + \left( {{\gamma _1} + {u_{1i}}} \right) * T\\ \\
\quad + \left( {{\gamma _2} + {u_{2i}}} \right) * {T^2} + \left( {{\gamma _3} + {u_{3i}}} \right) * {T^3} + {\varepsilon _{Ti}} \end{array}\end{equation*}
In the model, i indexes the child. The four γ terms in the model (γ0 through γ3) are constants providing the mean intercept, slope, quadratic, and cubic coefficients, respectively. The four u terms (u0i through u3i) adjust the mean parameters (intercept, slope, quadratic, and cubic coefficients) for between-child variation in SPHEQ. The ε term accounts for the scatter of an individual child's data about his cubic fit (i.e., the amount of error between the actual data for a given child and the cubic fit across all visits). Because of variation in model convergence, the random effects included in a model depended on which model was being fit. For the model with no predictors, random effects were included in the intercept, linear, quadratic, and cubic model terms. For the univariate models in the backward selection process, random effects were included in the intercept and linear model terms for all predictors but baseline SPHEQ. For the univariate model with baseline SPHEQ, random effects were included in the linear, quadratic, and cubic model terms. For the multivariate model, random effects were included in the linear, quadratic, and cubic model terms.
A predictor (P) was added to the base model in the following way:
\begin{equation*}
\!\!\!\!\!\!\!\!\!\!\!\!\!\!\!\!\!\!\!\!\!
\begin{array}{@{}l@{}} SPHE{Q_{Ti}} = \left( {{\gamma _{00}} + {\gamma _{01}} * {P_i} + {u_{0i}}} \right) + \left( {{\gamma _{10}} + {\gamma _{11}} * {P_i} + {u_{1i}}} \right) * T\\ \\
+ \left( {{\gamma _{20}} + {\gamma _{21}} * {P_i} + {u_{2i}}} \right) * {T^2} + \left( {{\gamma _{30}} + {\gamma _{31}} * {P_i} + {u_{3i}}} \right) * {T^3} + {\varepsilon _{Ti}} \end{array}\end{equation*}
Predictor terms were sequentially removed to produce more parsimonious univariate models. The removal began with the cubic term. If the cubic coefficient for the predictor, P, was statistically significant (p < 0.05), there were no changes made to the model. If it was not statistically significant, the cubic P term was removed, and the reduced model was fit. In the reduced model, if the quadratic P term was statistically significant, no additional changes were made to the model. If it was not, the quadratic P term was removed, and the reduced model was fit (i.e., a cubic base model with P terms limited to the intercept and slope). If necessary, the process was repeated for the linear P term and, finally, the intercept P term. If the intercept P term was not statistically significant, we concluded that the predictor had no effect on the progression of myopia. In multivariate modeling, all predictors were included in all the polynomial terms, even if their univariate models had simpler final configurations. Again, to achieve a parsimonious model, predictor terms that were not statistically significant were sequentially removed, using backward stepwise selection with the term with the biggest P value selected for removal. The cubic predictor terms were evaluated first, followed by the quadratic, linear, and intercept terms. There was no pruning of lower order predictor terms if a higher order term was statistically significant.
The authors thank Eric R. Ritchey, PhD (University of Houston College of Optometry), and Noel Brennan, MScOptom, PhD (Vistakon, Johnson & Johnson Vision Care, Inc.), for their useful feedback during manuscript preparation.
Supported by the National Eye Institute/National Institutes of Health Grants U10-EY08893 and R24-EY014792, the Ohio Lions Eye Research Foundation, the E.F. Wildermuth Foundation, and Johnson & Johnson Vision Care Inc.
The CLEERE Study Group (as of March 2012):
Franklin Primary Health Center, Inc.: Sandral Hullett, MD, MPH (Principal Investigator, 1997–2006); Robert N. Kleinstein, OD, MPH, PhD (Co-Investigator, 1997–2006); Janene Sims, OD (Optometrist, 1997–2001 and 2004–2006); Raphael Weeks, OD (Optometrist, 1999–2006); Sandra Williams (Study Coordinator, 1999–2006); LeeAndra Calvin (Study Coordinator, 1997–1999); Melvin D. Shipp, OD, MPH, DrPH (Co-Investigator, 1997–2004).
University of California, Berkeley School of Optometry, Berkeley, CA: Nina E. Friedman, OD, MS (Principal Investigator, 1999–2001); Pamela Qualley, MA (Study Coordinator, 1997–2001); Donald O. Mutti, OD, PhD (Principal Investigator, 1996–1999); Karla Zadnik, OD, PhD (Optometrist, 1996–2001).
University of Houston College of Optometry: Ruth E. Manny, OD, PhD (Principal Investigator, 1997–2006); Suzanne M. Wickum, OD (Optometrist, 1999–2006); Ailene Kim, OD (Optometrist, 2003–2006); Bronwen Mathis, OD (Optometrist, 2002–2006); Mamie Batres (Study Coordinator, 2004–2006); Sally Henry (Study Coordinator, 1997–1998); Janice M. Wensveen, OD, PhD (Optometrist, 1997–2001); Connie J. Crossnoe, OD (Optometrist, 1997–2003); Stephanie L. Tom, OD (Optometrist, 1999–2002); Jennifer A. McLeod (Study Coordinator, 1998–2004); Julio C. Quiralte (Study Coordinator, 1998–2005); Gaby Solis (Study Coordinator, 2005–2006).
Southern California College of Optometry, Fullerton, CA: Susan A. Cotter, OD, MS (Principal Investigator, 2004–2006, Optometrist, 1997–2004); Julie A. Yu, OD (Principal Investigator, 1997–2004; Optometrist 2005–2006); Raymond J. Chu, OD, MS (Optometrist, 2001–2006); Carmen N. Barnhardt, OD, MS (Optometrist 2004–2006); Jessica Chang, OD (Optometrist, 2005–2006); Kristine Huang, OD, MPH (Optometrist, 2005–2006); Rebecca Bridgeford (Study Coordinator, 2005–2006); Connie Chu, OD (Optometrist, 2004–2005); Soonsi Kwon, OD (Optometrist, 1998–2004); Gen Lee (Study Coordinator, 1999–2003); John Lee, OD (Optometrist, 2000–2003); Robert J. Lee, OD (Optometrist, 1997–2001); Raymond Maeda, OD (Optometrist, 1999–2003); Rachael Emerson (Study Coordinator, 1997–1999); Tracy Leonhardt (Study Coordinator, 2003–2004).
University of Arizona, Department of Ophthalmology and Vision Science, Tucson, AZ: J. Daniel Twelker, OD, PhD (Principal Investigator, 2000–2010); Mabel Crescioni, DrPh (Study Coordinator, 2009–2010); Dawn Messer, OD, MPH (Optometrist, 2000–2010); Denise Flores (Study Coordinator, 2000–2007); Rita Bhakta, OD (Optometrist, 2000–2004); Katie Garvey, OD (Optometrist, 2005–2008); Amanda Mendez Roberts, OD (Optometrist, 2008–2010).
Chairman's Office, The Ohio State University College of Optometry, Columbus, OH: Karla Zadnik, OD, PhD (Chairman, 1997–present); Jodi M. Malone Thatcher, RN (Study Coordinator, 1997–2012).
Videophakometry Reading Center, The Ohio State University College of Optometry, Columbus, OH: Donald O. Mutti, OD, PhD (Director, 1997–present); Huan Sheng, MD, PhD (Reader, 2000–2006); Holly Omlor (Reader, 2003–2006); Meliha Rahmani, MPH (Reader, 2004–2007); Jaclyn Brickman (Reader, 2002–2003); Amy Wang (Reader, 2002–2003); Philip Arner (Reader, 2002–2004); Samuel Taylor (Reader, 2002–2003); Myhanh T. Nguyen, OD, MS (Reader, 1998–2001); Terry W. Walker, OD, MS (Reader, 1997–2001); Vidhya Subramanian, MS (Reader, 2006–2007).
Optometry Coordinating Center, The Ohio State University College of Optometry, Columbus, OH: Lisa A. Jones-Jordan, PhD (Director, 1997–present); Linda Barrett (Data Entry Operator, 1997–2007); John Hayes, PhD (Biostatistician, 2001–2007); G. Lynn Mitchell, MAS (Biostatistician, 1998–present); Melvin L. Moeschberger, PhD (Consultant, 1997–2010); Loraine Sinnott, PhD (Biostatistician, 2005–present); Pamela Wessel (Program Coordinator, 2000–2017); Julie N. Swartzendruber, MA (Program Coordinator, 1998–2000); Austen Tanner (Data Entry Operator, 2008–2010).
Project Office, National Eye Institute, Rockville, MD: Donald F. Everett, MA.
Committees: Executive Committee: Karla Zadnik, OD, PhD (Chairman); Lisa A. Jones-Jordan, PhD; Robert N. Kleinstein, OD, MPH, PhD; Ruth E. Manny, OD, PhD; Donald O. Mutti, OD, PhD; J. Daniel Twelker, OD, PhD; Susan A. Cotter, OD, MS.
Disclosure: L.A. Jones-Jordan, None; L.T. Sinnott, None; R.H. Chu, None; S.A. Cotter, None; R.N. Kleinstein, None; R.E. Manny, None; D.O. Mutti, None; J.D. Twelker, None; K. Zadnik, Nevakar, Inc.